Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5897833 | Cytokine | 2013 | 10 Pages |
Abstract
The TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) superfamily that has been recognized for its specific pro-apoptotic effect on cancer cells and has been therefore proposed as a treatment in cancer. Studies on animal models have shown that TRAIL could also have a beneficial effect in rheumatoid arthritis (RA). This includes reports suggesting that TRAIL could be used to control the synovial hyperplasia and hyperactivation of immune cells observed in RA, but recent reports suggest a disease promoting role of TRAIL in RA. Indeed, adverse effects and mechanism of resistance could counteract beneficial effect of TRAIL. This review focuses on the role of TRAIL in immune regulation, synovial hyperplasia and joint remodeling in RA. We will also discuss the potential use of TRAIL in RA treatment.
Keywords
GM-CSFTNFTNF-related apoptosis-inducing ligand (TRAIL)fibroblast like synoviocytesXIAPFLICE-like inhibitory proteinDAS28FLIPOBSPBMCsAICDEAEOCsAIAMcl-1RANKLArthritisantigen-induced arthritisRheumatoid arthritisexperimental autoimmune encephalitisOsteoblastsOsteoclastsinterferonIFNinterleukineJoint destructionAuto-immunityperipheral-blood mononuclear cellsgranulocyte-macrophage colony-stimulating factortumor necrosis factorTRAILTNF-related apoptosis-inducing ligandactivation-induced cell deathMultiple sclerosisdisease activity score in 28 jointsX-linked Inhibitor of Apoptosis ProteinGlucocorticoid
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Rachel Audo, Bernard Combe, Michael Hahne, Jacques Morel,